Recombinant Human CCL18/PARC Protein(Trx Tag) (PDEH100610)
For research use only.
| Synonyms | CKb, TSC, DCCK, DC-CK, Eotaxin, AMAC-1, CCL26, CKb7, DC-CK1, Eotaxin-3, IMAC, MIP-4, MIP-4a, SCYA26, TSC-1, AMAC1, MIP4, PARC, SCYA18, CCL18, AMAC-1, CKb7, DCCK1, DC-CK1, MIP-4, Alternative macrophage activation associated CC chemokine 1, Alternative macrophage activation-associated CC chemokine 1, CC chemokine PARC, C-C Motif Chemokine 18, CCL18(4-69), Dendritic cell chemokine 1, Macrophage inflammatory protein 4, Pulmonary and activation regulated chemokine, Pulmonary and activation-regulated chemokine, Small inducible cytokine A18, Small-inducible cytokine A18 |
| Species | Human |
| Expression Host | E.coli |
| Sequence | Ala21-Ala89 |
| Accession | P55774 |
| Calculated Molecular Weight | 27.4 kDa |
| Observed Molecular Weight | 30 kDa |
| Tag | N-Trx |
| Bio-activity | Not validated for activity |
| Purity | > 90% as determined by reducing SDS-PAGE. |
| Endotoxin | < 10 EU/mg of the protein as determined by the LAL method |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis. |
| Background | CCL18/PARC is a chemotactic cytokine involved in the pathogenesis and progression of various disorders, including cancer. Proof showed high levels of CCL18/PARC in the serum of epithelial ovarian carcinoma patients sμggesting its potential as a circulating biomarker. CCL18/PARC chemokine has an important role in chemokine-mediated tumor metastasis, and may serve as a potential predictor for poor survival outcomes for ovarian cancer. (CCL18/PARC) is predominantly secreted by M2-tumor associated macrophages (TAMs) and promotes malignant behaviors of various human cancer types. CCL18/PARC has a correlation with cardiac function in patients with AAMI and it might be considered as an indicator of poor LVEF in patients with AAMI. Circulating and WAT-secreted CCL18/PARC correlates with insulin resistance and metabolic risk score. Because CCL18/PARC is macrophage-specific and associates with adipose immune gene expression, it may constitute a marker of WAT inflammation. Macrophages are thoμght to be the main source of CCL18/PARC, and the effect of pirfenidone, an anti-fibrotic agent for idiopathic pulmonary fibrosis, on the expression of CCL18/PARC in macrophages warrants investigation. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
